NASDAQ$LGND
Ligand Pharmaceuticals Incorporated · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported strong financial results, executed on investment strategy, and increased 2023 guidance.
Ligand Pharmaceuticals reported strong Q3 2023 financial results with total revenues of $32.9 million, and royalties of $23.9 million. The company actively executed its investment strategy, investing over $75 million in Tolerance, Ovid, Novan and Primrose transactions. Ligand is increasing its 2023 revenue guidance to be in the range of $126 million to $129 million and is raising adjusted EPS guidance to $5.25 to $5.40.
- Total revenues for Q3 2023 were $32.9 million; revenues for the same period in 2022 excluding COVID-19 sales were $26.9 million.
- Royalties for Q3 2023 were $23.9 million, compared to $19.3 million for the same period in 2022.
- Core Captisol sales were $8.6 million for Q3 2023, compared to $3.6 million for the same period in 2022.
- Adjusted net income from continuing operations for Q3 2023 was $18.0 million, or $1.02 per diluted share, compared to $10.5 million, or $0.60 per diluted share, for the same period in 2022.
Headline financials
Revenue & EPS history
Ligand · Revenue · Quarterly
$32.9M
Revenue by segment
Ligand · $23.9M total across 1 segment · Q3 2023
- Royalties$23.9M+20.3%100.0%
Forward guidance
Ligand is increasing its 2023 revenue guidance to be in the range of $126 million to $129 million (previously $124 million to $126 million) and is raising adjusted EPS guidance. Sales of Captisol are now expected to range from $27 million to $28 million (previously $25 million).
Tailwinds
- Increased revenue guidance for 2023 to $126 million - $129 million.
- Raised adjusted EPS guidance for 2023 to $5.25 - $5.40.
- Captisol sales are now expected to range from $27 million to $28 million.
- Primrose Bio transaction is expected to reduce ongoing cash expenses and be immediately accretive to Ligand's adjusted EPS.
- Acquisition of Tolerance Therapeutics is expected to be immediately accretive to Ligand's royalty revenue.
Headwinds
- Unpredictable nature of the pandemic and related Captisol sales.
- Potential delays or inability to meet Captisol demands of its partners.
- Risks associated with integrating acquisitions with Ligand’s existing businesses.
- Ligand may not be able to acquire, stabilize, outlicense or sell Novan's programs or assets.
- Ongoing or future litigation could expose Ligand to significant liabilities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+0.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
52%
33 / 64 earnings
Positive
+18.7%
Q4 2013
Best reaction
-21.6%
Q3 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | +5.0% | — | |
| Q4 2025 | +2.6% | +6.7% | +2.1% | |
| Q3 2025 | +9.3% | +9.6% | -2.9% | |
| Q1 2025 | -3.2% | +0.0% | +0.4% | |
| Q4 2024 | +0.6% | +0.2% | -6.4% | |
| Q3 2024 | +3.7% | +3.3% | +6.8% | |
| Q2 2024 | -4.9% | +2.1% | +5.1% | |
| Q1 2024 | +10.3% | +19.8% | +13.1% | |
| Q4 2023 | +13.3% | +5.8% | -1.8% | |
| Q3 2023 | +2.8% | +3.8% | +16.3% | |
| Q2 2023 | +6.7% | +1.4% | -4.2% | |
| Q1 2023 | +5.2% | +3.2% | -0.2% | |
| Q4 2022 | +5.9% | +3.0% | -2.1% | |
| Q3 2022 | +12.8% | +31.3% | +6.0% | |
| Q2 2022 | +5.7% | +9.5% | -3.5% | |
| Q1 2022 | -2.9% | -13.0% | -9.1% | |
| Q4 2021 | -16.3% | -19.7% | -8.7% | |
| Q3 2021 | +7.8% | +4.9% | -6.9% | |
| Q2 2021 | -8.1% | -10.0% | -7.4% | |
| Q1 2021 | -9.5% | -10.5% | -22.3% | |
| Q4 2020 | +1.7% | +17.6% | -18.5% | |
| Q3 2020 | -0.2% | +5.4% | +3.4% | |
| Q2 2020 | +0.6% | +0.4% | -11.9% | |
| Q1 2020 | +3.2% | +6.8% | +22.1% | |
| Q4 2019 | +3.3% | +2.8% | +16.7% | |
| Q3 2019 | -7.4% | -1.4% | -4.9% | |
| Q2 2019 | -14.8% | -11.5% | -14.7% | |
| Q1 2019 | -3.3% | -4.1% | -14.6% | |
| Q4 2018 | -2.7% | +1.8% | -10.0% | |
| Q3 2018 | -2.7% | -8.9% | -10.7% | |
| Q2 2018 | +9.8% | +7.7% | +13.0% | |
| Q1 2018 | +7.3% | +13.2% | +26.4% | |
| Q4 2017 | +0.0% | -1.9% | +3.7% | |
| Q3 2017 | -4.9% | -1.3% | -8.4% | |
| Q2 2017 | +5.7% | +2.5% | +9.4% | |
| Q1 2017 | -2.9% | +0.2% | +1.2% | |
| Q4 2016 | -2.8% | +1.3% | +1.5% | |
| Q3 2016 | -2.7% | +3.1% | +10.8% | |
| Q2 2016 | -7.4% | -13.2% | -20.2% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +5.1% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | +4.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q1 2014 | -2.9% | — | — | |
| Q4 2013 | +18.7% | — | — | |
| Q3 2013 | -10.7% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q1 2013 | +1.7% | — | — | |
| Q4 2012 | +7.4% | — | — | |
| Q3 2012 | +10.8% | — | — | |
| Q2 2012 | -8.8% | — | — | |
| Q4 2011 | -8.8% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q3 2011 | -21.6% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q4 2010 | -0.3% | — | — | |
| Q3 2010 | -2.4% | — | — | |
| Q2 2010 | -3.6% | — | — | |
| Q1 2010 | -9.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro